Close
Achema middle east
swop processing & packaging

Sandoz announces launch of piperacillin and tazobactam for injection, a generic version of Zosyn

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Sofinnova Partners Raises $750mn to Support Biotech Startups

European venture capital firm Sofinnova Partners said on November...

J&J Buys Halda for $3bn to Own the Cell Death Platform

Johnson & Johnson will be paying $3.05 billion so...

Pharma Grade Supplements vs. Food Grade Supplements

In recent years, dietary supplements have become a major...

Eli Lilly Commits $1.2bn to Modernize Puerto Rico Manufacturing

Governor Jenniffer A. González Colón, along with Sebastián Negrón...
- Advertisement -

Sandoz anounced the launch of piperacillin and tazobactam for injection, a generic equivalent of Zosyn®, in the US. Piperacillin and tazobactam for injection is an antibacterial treatment indicated for use in adults with certain types of moderate to severe infections caused by piperacillin-resistant, piperacillin/tazobactam susceptible, ß-lactamase producing strains. Don DeGolyer, President of Sandoz Inc said, Sandoz has a long history of global leadership in developing high-quality, affordable anti-infective medicines. The US launch of piperacillin and tazobactam for injection, or generic Zosyn®, further strengthens our portfolio in this key field as well as our commitment to differentiated products, including injectables

According to IMS Health, branded and generic versions of piperacillin and tazobactam for injection had US sales of approximately USD 797 million for the 12 months ending in August 2010. Sandoz is marketing piperacillin and tazobactam for injection in 2.25 g, 3.375 g and 4.5 g vials, the same standard vial strengths marketed for Zosyn®.

Latest stories

Related stories

Sofinnova Partners Raises $750mn to Support Biotech Startups

European venture capital firm Sofinnova Partners said on November...

J&J Buys Halda for $3bn to Own the Cell Death Platform

Johnson & Johnson will be paying $3.05 billion so...

Pharma Grade Supplements vs. Food Grade Supplements

In recent years, dietary supplements have become a major...

Eli Lilly Commits $1.2bn to Modernize Puerto Rico Manufacturing

Governor Jenniffer A. González Colón, along with Sebastián Negrón...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »